Official Title
Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes
Brief Summary

The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the COVID-19 infection

Not yet recruiting
Coronavirus Infection
Type 2 Diabetes

Drug: Linagliptin
5 mg Linagliptin administered by mouth once daily
DPP4 group
Other Name: Tradjenta

Drug: Insulin regimen
Standard of care insulin regimen as per hospital protocol
Control group

Eligibility Criteria

Inclusion Criteria: - Type 2 Diabetes Mellitus (T2DM) as per American Diabetes Association (ADA) guidelines - Age ≥ 18 - Confirmed COVID-19 - Mild COVID-19 defined as any of the following: fever, malaise, cough, headache, sore throat, myalgia, nasal congestion, diarrhea - Moderate COVID-19 is defined as > 2 of the following in non-intubated patients: any symptom of mild disease, radiographic imaging (chest x-ray or lung ultrasound) with bilateral ground glass opacities or bilateral consolidations, SpO2

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
United States
Locations

University of Miami
Miami, Florida, 33136

Contacts

Gianluca Iacobellis, MD PhD
3052433636
giacobellis@med.miami.edu

Gianluca Iacobellis, MD PhD
Principal Investigator
University of Miami

University of Miami
NCT Number
Keywords
Covid-19
SARS-CoV 2
DPP4
Type 2 diabetes
MeSH Terms
Coronavirus Infections
Severe Acute Respiratory Syndrome
Diabetes Mellitus, Type 2
Linagliptin